Antoni Wiedlocha funded by the EEA Poland-Norway grants
Antoni Wiedlocha
The proposal "Novel targeted therapy based on dual warhead conjugates against FGFR dependent cancers", with senior scientist Antoni Wiedlocha at Department of Molecular Cell Biology, Institute for Cancer Research, as Norwegian partner and professor Jacek Otlewski at the University of Wroclaw as Polish parther, has been awarded funding from the EEA Poland-Norway grants under the "Applied Research" programme.
Links:
From the National Centre for Research and Development in Poland:
Published in Level 2 journals, first or last author from Oslo University Hospital.
Mørk R, Bøyesen P, Kindem IA, Lilleby J, Gunnarsson R, Molberg Ø, Lilleby V(2025) Avacopan as an add-on therapy in a paediatric patient with new-onset granulomatosis with polyangitiis and acute kidney injury: a case report Rheumatology (Oxford)(in press) DOI 10.1093/rheumatology/keaf523, PubMed 41075162
Bergan-Dahl A, Carlson CR, Laasmaa M, Subramanian H, Basson A, Li J, Hasic A, Lunde M, Ugland H, Manfra O, Klussmann E, Bossuyt J, Bers DM, Nikolaev VO, Louch WE, Shen X(2025) Activated CaMKIIδ translocates to the RyR nanodomain in cardiomyocytes Cardiovasc Res(in press) DOI 10.1093/cvr/cvaf187, PubMed 41071938
Westerberg AC, Degnes ML, Andresen IJ, Sellevoll H, Lekva T, Ueland T, Bergman L, Henriksen T, Roland MCP, Zucknick M, Michelsen TM(2025) Placenta-Derived Proteins in Preeclampsia: A Human In Vivo Study Hypertension(in press) DOI 10.1161/HYPERTENSIONAHA.125.24886, PubMed 41064898